Emotional Brain has announced that the United States Patent and Trademark Office (USPTO) has awarded a new patent (US Patent No. 8,227,453, issued today) for its combination of a PDE5-inhibitor and testosterone for the treatment of Female Sexual Dysfunction (FSD).
There is no FDA-approved medicine available yet for this particular indication area, so American physicians annually prescribe off-label drugs for the treatment of FSD. Dr Adriaan Tuiten, PhD, CEO of Emotional Brain, explains, 'It ensures protection of our medical applications and medical procedures aimed at the treatment of Female Sexual Dysfunction. The issuance of new patents in a country such as the United States is tremendously important and has a huge impact.'